Shamil R. Kzyrgalin

Shamil R. Kzyrgalin

Auto-generated profile, based on publicly available information

Shamil R. Kzyrgalin

Bashkir State Medical University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
SGSh. Kh. Gantsev
Sh. Kh. Gantsev
MZM. V. Zabelin
M. V. Zabelin
KGK. Sh. Gantsev
K. Sh. Gantsev
AIA. A. Izmailov
A. A. Izmailov
SKSh. R. Kzyrgalin
Sh. R. Kzyrgalin
Peritoneal carcinomatosis (PC) is a global challenge of modern oncology representing the most unfavourable scenario in diverse-locality tumourisation. Despite certain attention by the oncological community, the management of PC patients is currently palliative, which weakly promotes research into the basic principles of this morbidity. This literature review attempts to comprehensively cover the PC problematic from a global perspective and presents a key evidence on the world schools of thought in this area. Briefly taking, peritoneal carcinomatosis is viewed today as a local process in the conventional implantation theory, which imposes a locoregional character on all current or emerging therapies, such as cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Their inadequate efficacy is largely due to pronounced gaps in our understanding of PC logistics and signalling. PSOGI is a key organisation for centralising the specialty effort in peritoneal carcinomatosis. Despite its global geography and approach to PC discussion, a multitude of scientific questions remain unanswered impeding the establishment of novel effective therapies. The seven countries that nurtured distinguished schools of thought in PC studies are the USA, UK, Japan, China, Italy, France and Germany. Taking peritoneal carcinomatosis in a global perspective, an insufficient attention to its problematic in Russia should be addressed. The founding and fostering of national PC institutions will benefit cancer patients and progress in oncological science.

22 May 2021 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
SGSh. Kh. Gantsev
Sh. Kh. Gantsev
KGK. Sh. Gantsev
K. Sh. Gantsev
SKSh. R. Kzyrgalin
Sh. R. Kzyrgalin
KIK. R. Ishmuratova
K. R. Ishmuratova
Peritoneal carcinomatosis is viewed by many experts as a terminal illness with an unfavourable course and prognosis. Existing therapies are controversial and exhibit ambiguous efficacy. We review the current state of the art in therapy for peritoneal metastases of various origin and its historical background. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy compound the treatment of choice as achieving the highest survival rates. Palliative surgery and systemic chemotherapy are an alternative that proved even more aggressive and ineffective in comparative survival evaluations. Manifold studies and expert opinions exist on the efficacy and expedience of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treatment of peritoneal carcinomatosis. Today, however, their routine use in everyday practice is hotly debated. Despite an evident progress in managing peritoneal metastases, a series of questions remain unsolved. Contentious research data, late diagnosis, low treatment efficacy in severe peritoneal dissemination, a limited applicability of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, all highlight the importance of inventing and developing novel methods for early high-accuracy diagnosis and careful selection of the treatment strategy. Fundamental knowledge of malignant metastasis underlies the choice of patient management and the innovative toolkit for prevention and treatment of peritoneal carcinomatosis.

22 March 2019 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
SGSh. Kh. Gantsev
Sh. Kh. Gantsev
VMV. M. Moiseenko
V. M. Moiseenko
KGK. Sh. Gantsev
K. Sh. Gantsev
ССС. В. Соломенный
С. В. Соломенный
SKSh. R. Kzyrgalin
Sh. R. Kzyrgalin
RMR. S. Minigazimov
R. S. Minigazimov
Минерализация брюшины — новая мишень в терапии перитонеального канцероматоза

30 June 2023 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
SKSh. R. Kzyrgalin
Sh. R. Kzyrgalin
RYR. S. Yamidanov
R. S. Yamidanov
KNKsenia Nazmieva
Ksenia Nazmieva
SGSh. Kh. Gantsev
Sh. Kh. Gantsev
Cancer is one of the most common diseases in the world. Th e transcription factor NF-κB plays a key role in various physiological processes including immune response, cell proliferation, cell apoptosis and inflammation. Due to participation of NF-kappa B signaling pathways in carcinogenesis, angiogenesis, and tumor resistance to chemo- and radiotherapy, the factor is considered to be the ideal target for pharmacological treatment of cancer. Th e paper presents a literature review of the RSCI, PubMed, Scopus, Web of Science, Chemical Abstracts NCCN databases and other open access data. The carcinogenesis inhibitors were selected from all NF-κB inhibitors found. Inhibitors with antitumor activity of analytical interest include Bruton tyrosine kinase (BTK) inhibitors, cellular inhibitors of apoptosis proteins (c-IAP), proteasome inhibitors, and one inhibitor of NF-κB translocation to the nucleus. Th e authors analyzed products of diff erent development stages with recorded antitumor activity to varying degrees. NF-κB inhibitors are promising drug candidates, but since NF-κB is involved in most biological processes and the broad spectrum of action can cause side eff ects, the selective action of these compounds is to be explored.

22 May 2021 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
SGSh. Kh. Gantsev
Sh. Kh. Gantsev
GSG. Schaller
G. Schaller
KGK. Sh. Gantsev
K. Sh. Gantsev
APA. N. Plikhta
A. N. Plikhta
SKSh. R. Kzyrgalin
Sh. R. Kzyrgalin
RRR. A. Rustamkhanov
R. A. Rustamkhanov
Introduction. Neuroendocrine breast tumors represent a rare subtype of breast cancer, accounting for less than 1 % of all neuroendocrine neoplasms. Starting from their pathology definition, and going through their prevalence, prognosis and treatment, our knowledge is still really uncertain.Materials and methods. The article presents a rare clinical observation of a neuroendocrine breast tumor. A breast fibroadenoma was diagnosed at the initial diagnosis stage in a private clinic; after a surgical treatment and further morphological study, it was estimated: a diagnosis of Cancer in situ of the left breast T1N0M0, stage I. Next, 3D-conformal remote radiation therapy was performed on the area of the left breast.Results and discussion. After conducting positron emission tomography, multiple metastases were detected in the lymph nodes, bones, and liver. Additionally, micropreparations were consulted at the Federal Reference Center in St. Petersburg and at an independent third-party molecular biological laboratory in Germany (Munich). Given all the instrumental, molecular biological, histological and immunohistochemical studies of the patient, an individual regimen of drug therapy was selected.Conclusion. After 18 months of personalized drug therapy, we observed a positive trend and a significant decrease in metabolic activity according to positron emission tomography.

13 April 2021 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
KUKazuo Umezawa
Kazuo Umezawa
SGSh. Kh. Gantsev
Sh. Kh. Gantsev
SKSh. R. Kzyrgalin
Sh. R. Kzyrgalin
RYR. S. Yamidanov
R. S. Yamidanov
RAR. A. Amirov
R. A. Amirov
EZE. I. Zhuk
E. I. Zhuk
Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in solid and haematopoietic tumour cells. One of the best known NF-κB functions is expression regulation of genes involved in the apoptosis inhibition or activation and survival in both intact and malignant cells. The NF-κB-mediated pathways’ involvement in carcinogenesis, angiogenesis and tumour resistance to chemo- and radiotherapies makes this factor a promising target for drug anti-cancer interventions. This review summarises evidence on the antitumour and anti-inflammatory activity of a high-potent and specific low molecular-weight NF-κB inhibitor, dehydroxymethylhepoxyquinomycin (DHMEQ), as a candidate therapeutic agent in treatment for variant malignancies.